Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Developing an imaging biomarker based on hemodynamic impairment to predict the development of Alzheimer’s disease
EF 2015-16
Résumé
With the aging global population, the socio-economic burden of Alzheimer's disease (AD) is expected to dramatically increase. It is imperative that the medical system commits to developing effective tools to combat this debilitating disease. With promising disease-modifying therapies on the horizon, identifying which type of dementia a patient is experiencing will become critical in order to start treatment as soon as possible. While it is already understood that one subtype of dementia, vascular dementia, is the direct result of injury to blood vessels in the brain, the role of vascular insult in the development of other types of dementia has yet to be fully elucidated. There is now converging evidence indicating that blood vessel damage plays an important role in Alzheimer's disease. The Mikulis Lab has constructed a safe and effective tool that can assess how well vessels in the brain are able to regulate blood flow to support increases in metabolic demand. We aim to study the contribution of vascular injury to the development of Alzheimer's dementia by comparing cerebrovascular reserve (CVR) in healthy controls and in patients with mild cognitive impairment (MCI) and mild AD.When carbon dioxide is inhaled, healthy vessels will increase flow, however in unhealthy vessels, this mechanism is impaired. We believe that unhealthy blood vessels will be present in areas at a very early stage of dementia before any measurable change in cerebral blood flow or grey matter volume.Success in this regardcould lead to a testable biomarker based on CVR that may eventually enable earlier diagnosis andmanagement of AD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
349973
Name
Holmes Kenneth R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing an imaging biomarker based on hemodynamic impairment to predict the development of Alzheimer’s disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Cerebrovascular Reactivity; Hemodynamic Impairment; Magnetic Resonance Imaging; Mild Cognitive Impairment
Abstract
With the aging global population, the socio-economic burden of Alzheimer's disease (AD) is expected to dramatically increase. It is imperative that the medical system commits to developing effective tools to combat this debilitating disease. With promising disease-modifying therapies on the horizon, identifying which type of dementia a patient is experiencing will become critical in order to start treatment as soon as possible. While it is already understood that one subtype of dementia, vascular dementia, is the direct result of injury to blood vessels in the brain, the role of vascular insult in the development of other types of dementia has yet to be fully elucidated. There is now converging evidence indicating that blood vessel damage plays an important role in Alzheimer's disease. The Mikulis Lab has constructed a safe and effective tool that can assess how well vessels in the brain are able to regulate blood flow to support increases in metabolic demand. We aim to study the contribution of vascular injury to the development of Alzheimer's dementia by comparing cerebrovascular reserve (CVR) in healthy controls and in patients with mild cognitive impairment (MCI) and mild AD.When carbon dioxide is inhaled, healthy vessels will increase flow, however in unhealthy vessels, this mechanism is impaired. We believe that unhealthy blood vessels will be present in areas at a very early stage of dementia before any measurable change in cerebral blood flow or grey matter volume.Success in this regardcould lead to a testable biomarker based on CVR that may eventually enable earlier diagnosis andmanagement of AD.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Holmes, Kenneth R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~